['psoriasis']
['las41004', 'control']

        Inclusion Criteria (main):

          -  mild to moderate stable chronic plaque-type psoriasis with at least two symmetrical
             lesions with a treatment area of 20 - 300 cm² and a TSS of ≥ 6;

               -  female volunteers of childbearing potential* must agree to use appropriate and
                  reliable methods of contraception

               -  written informed consent obtained.

        Exclusion Criteria (main):

          -  severe forms of psoriasis or forms of psoriasis other than chronic plaque psoriasis,

          -  treatment with any locally acting medications which might counter or influence the
             trial aim within 2 weeks preceding the treatment phase of the trial and during the
             trial;

          -  treatment with any systemic medications which might counter or influence the trial aim
             or phototherapy/PUVA within 4 weeks preceding the treatment phase of the trial and
             during the trial;

          -  treatment with vitamin A supplements;

          -  treatment with any biologics within 3 months preceding the treatment phase of the
             trial and during the trial, or in the case of ustekinumab, within 6 months;

          -  treatment with any immunosuppressive medication within 6 months preceding the
             treatment phase of the trial and during the trial;

          -  known allergic reactions, irritations or hypersensitivity to the active ingredients

          -  contraindications according to summary of product characteristics (SmPC) of the active
             comparator: - pregnancy or nursing;
      